Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral levosimendan for respiratory function in ALS
NL-OMON50701Phase 3Active, not recruiting
- Sponsor
- Orion Corporation
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Levosimendan with Placebo (2 arms). Primary endpoints: Change from baseline in supine slow vital capacity at 12 weeks, ALSFRS-R and 7 more. Started Nov 2018; status: active, not recruiting.
02
Drugs
levosimendan
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON50701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50701.